Chromatin-Bound PARP1 Correlates with Upregulation of Inflammatory Genes in Response to Long-Term Treatment with Veliparib
Isabel Alvarado-Cruz(University of Arizona), Joann B. Sweasy(Susan Thompson Buffett Foundation), Daniel J. Laverty(Massachusetts Department of Public Health), Yong Kong(W. M. Keck Foundation), Michael Krauthammer(University of Zurich), Mohammed Imran Khan(New York University), Rithy Meas(University of Arizona), Kurt A. Schalper(Yale University), Hailey Wyatt(Yale University), Kaylyn Clairmont(Yale University), Angelo Porciuncula(Yale University), Yu Shyr(Vanderbilt University), Patricia LoRusso(Yale Cancer Center), Shuangge Ma(Yale University), Sebastian Oeck(Essen University Hospital), Victoria Quintana(University of Arizona), Zachary D. Nagel(Harvard University), Ying Zhu(Yale University), Shilin Zhao(Vanderbilt University), Mariam M. Mahmoud(Yale University)
Cited by 0
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
|The Lancet Oncology|2012|1.3k
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis
|Cancer Cell|2004|1.1k
Regularized gene selection in cancer microarray meta-analysis
|BMC Bioinformatics|2009|839
Programmed death ligand-1 expression in non-small cell lung cancer
|Laboratory Investigation|2013|753